Impact BioMedical to Effect 1-for-12.62 Reverse Stock Split

04:32 PM EDT, 09/11/2026 (MT Newswires) -- Impact BioMedical (IBO) said late Friday its board approved a 1-for-12.62 reverse stock split, effective Sept. 23, as part of efforts to support its business combination with Zoar and continued listing objectives. The split will lower the company's outstanding common shares to over 8.5 million from 107.8 million, according to a statement. Upon completion of the proposed business combination, Impact BioMedical stockholders are expected to receive one share of Zoar for every four shares of Impact held, the company said.